Patent ID: 8278265

Claim:
A composition comprising a conjugate of crotamine consisting of SEQ ID No. 1 and a pharmaceutically effective compound for treating cancer, wherein: (i) aa 1-3 of SEQ ID No. 1 are selected from the group consisting of basic amino acid residues and non-carried polar amino acid residues; (ii) aa 5-10 of SEQ ID No. 1 are selected from the group consisting of basic amino acid residues and non-polar amino acid residues; (iii) aa 12-17 of SEQ ID No. 1 are selected from the group consisting of basic amino acid residues, acid amino acid residues and non-polar amino acid residues; (iv) aa 19-29 of SEQ ID No. 1 are selected from the group consisting of basic amino acid residues, acid amino acid residues, non-carried polar amino acid residues and non-polar amino acid residues; (v) aa 31-35 of SEQ ID No. 1 are selected from the group consisting of basic amino acid residues and non-polar amino acid residues; and (vi) aa 38-42 of SEQ ID No. 1 are selected from the group consisting of basic amino acid residues, non-carried polar amino acid residues and non-polar amino acid residues, wherein the crotamine is present in an amount of 100 μM to 0.1 μM effective for the delivery of the pharmaceutically effective compound into cells.